2 completed, 1 withdrawn. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Fuchs Endothelial Corneal Dystrophy: new trials by email Literature Review of Fuchs Endothelial Corneal Dystrophy trials Research Report on Fuchs Endothelial Corneal Dystrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3 QR-504a - Fuchs Endothelial Corneal Dystrophy, FECD3 | Phase 1 | Withdrawn | ProQR Therapeutics | 2021-08-10 | 2022-05-11 | |
| Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema EO2002, EO2002 low dose, EO2002 mid dose - Corneal Edema, Corneal Endothelial Dysfunction | Phase 1 | Completed | Emmecell | 42 | 2021-06-22 | 2025-03-05 |
| A Phase 1/ Phase 2 Study of TTHX1114(NM141) TTHX1114(NM141), Vehicle (placebo) - Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy | Phase 1 / Phase 2 | Completed | Trefoil Therapeutics, Inc. | 22 | 2020-08-19 | 2023-10-30 |
Fuchs' Endothelial Dystrophy (3) · Corneal Dystrophy, Posterior Polymorphous, 1 (2) · Corneal Diseases (1) · Corneal Edema (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Corneal Dystrophies, Hereditary (3) · Eye Diseases (3) · Eye Diseases, Hereditary (3) · Genetic Diseases, Inborn (3) · Corneal Diseases (2)
Emmecell (1) · ProQR Therapeutics (1) · Trefoil Therapeutics, Inc. (1)
United States (2) · United Kingdom (1)
Noelia Kunzevitzky (1) · Thomas M Tremblay, RN BSN (1)